New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:55 EDTSTEMStemCells says interim Phase I/II trial data show slowing of AMD progression
StemCells reported interim results from its Phase I/II clinical trial of the company's proprietary HuCNS-SC human neural stem cell platform in dry age-related macular degeneration, or AMD, yesterday evening at the 12th annual meeting of the International Society for Stem Cell Research in Vancouver, Canada. Interim trial results show a 65% reduction in the rate of geographic atrophy, or GA, in the study eye when compared to the expected natural history of the disease as well as a 70% reduction in the rate of GA when compared to the control eye. Stephen Huhn, chief medical officer at StemCells, said "The interim data are very encouraging from two separate perspectives. First, the reduction in the rate of geographic atrophy suggests the HuCNS-SC cells are affecting the underlying cause of AMD. Secondly, the data demonstrates there are increases in contrast sensitivity, which is a vital aspect of visual function. Impacting the progression of GA and enhancing visual function could have a very meaningful impact on the quality of life for AMD patients and the results to date strongly support our plans to initiate a randomized, controlled, Phase II proof-of-concept trial later this year."
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for STEM

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use